ストックスクリーナーアプリを入手
1.02
0.00%
0.00
アフターアワーズ：
1.00
-0.02
-1.96%
前日終値:
$1.02
開ける：
$1
24時間の取引高:
30,956
Relative Volume:
0.45
時価総額：
$43.15M
収益：
-
当期純損益:
$-74.56M
株価収益率:
-0.5226
EPS:
-1.9516
ネットキャッシュフロー:
$-60.27M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
-8.11%
6か月 パフォーマンス:
-44.26%
1年 パフォーマンス:
-75.36%
1日の値動き範囲:
$1.00
$1.04
1週間の範囲:
$0.995
$1.08
52週間の値動き範囲:
$0.9616
$4.20
Rallybio Corp Stock (RLYB) Company Profile
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-04-17 | 開始されました | H.C. Wainwright | Buy |
| 2023-04-10 | 開始されました | Wedbush | Outperform |
| 2022-12-09 | 開始されました | JP Morgan | Overweight |
| 2022-02-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-08-23 | 開始されました | Cowen | Outperform |
| 2021-08-23 | 開始されました | Evercore ISI | Outperform |
| 2021-08-23 | 開始されました | Jefferies | Buy |
すべてを表示
Rallybio Corp (RLYB) 最新ニュース
Two former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotech - PharmaVoice
Rallybio stock plunges to 52-week low at $0.99 amid market challenges - Investing.com Canada
Rallybio advances novel FNAIT prevention trial By Investing.com - Investing.com Canada
Rallybio advances novel FNAIT prevention trial - Investing.com India
Rallybio stock plunges to 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
Rallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved - TipRanks
Rallybio to Begin First Clinical Trial for Prevention of Rare Pregnancy Blood Disorder - Femtech Insider
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT - StockTitan
Rallybio stock hits 52-week low at $1.08 amid market challenges - Investing.com Australia
Rallybio stock plunges to 52-week low at $1.08 amid market challenges - Investing.com
Rallybio shares hold Buy rating on HPP treatment data - Investing.com India
Rallybio's SWOT analysis: FNAIT treatment stock poised for growth amid challenges - Investing.com
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting - StockTitan
Rallybio reveals higher FNAIT risk across populations By Investing.com - Investing.com Australia
Rallybio reveals higher FNAIT risk across populations - Investing.com
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting - Business Wire
Rallybio Co. (NASDAQ:RLYB) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Rallybio announces board member resignation - Investing.com
Rallybio announces board member resignation By Investing.com - Investing.com UK
Dr. Kush Parmar Steps Down from Rallybio’s Board and Committee - TipRanks
Rallybio Corporation Announces Resignation of Kush Parmar as Member of Board and Chair of Nominating and Corporate Governance Committee, Effective October 31, 2024 - Marketscreener.com
RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit - Business Wire
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree - Business Wire
Rallybio - FiercePharma
Rallybio stock plunges to 52-week low, hits $1.09 - Investing.com
Rallybio (NASDAQ:RLYB) Given “Buy” Rating at HC Wainwright - Defense World
Rallybio reiterated at Buy at H.C. Wainwright on FNAIT drug data - Investing.com
Rallybio advances RLYB212 to phase 2 for FNAIT prevention - Investing.com India
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis - Business Wire
We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully - Simply Wall St
Rallybio to Present at Upcoming Investor Conferences - Elk Valley Times
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Rallybio stock plunges to 52-week low at $1.09 amid market challenges - Investing.com Australia
HC Wainwright Comments on Rallybio Co.’s Q3 2024 Earnings (NASDAQ:RLYB) - Defense World
H.C. Wainwright lowers Rallybio shares target, sees potential in FNAIT treatment - Investing.com
Rallybio (NASDAQ:RLYB) PT Lowered to $6.00 - Defense World
Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth? - Yahoo Finance
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates - StockTitan
Rallybio stock plunges to 52-week low at $1.12 amid market challenges - Investing.com
Rallybio Corp (RLYB) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):